Manhattan recording for client financial results

We filmed high above the Manhattan skyline in New York City for the full year financial results announced by our client

Volition RX, quoted on the New York Stock Exchange…and there was an exciting announcement made by the company.

The highlights of the interview included:

• Executed global licensing and supply agreement with Heska Corporation to distribute Nu.Q® Vet Cancer Screening Test at the Point of Care with a $10 million upfront payment and up to $18 million based upon the achievement of near/mid-term milestones.
• Under said agreement will receive ongoing additional revenue for key components and kits.
• In advanced negotiations with other potential licensing partners in efforts to make Nu.Q® Vet as accessible as possible worldwide.
• Expanded its intellectual property portfolio.
• Made significant progress with its Nu.Q^® NETs development.
• Continued progress towards additional new product launches and licensing in both the human and veterinary spaces worldwide.
• Approximately $20.6 million in cash and cash equivalents on the balance sheet as of December 31, 2021.

“I could not be prouder of the team’s achievement in securing a global licensing and supply agreement for our Nu.Q® Vet Cancer Screening Test with Heska Corporation, one of the industry’s leading companies,” commented Cameron Reynolds, President and Group Chief Executive Officer of Volition.

“Volition Veterinary is an exciting, fast-moving part of our business with clear potential to generate significant revenue for the company, initially under our agreements with Heska and SAGE Healthcare, through both milestone payments and ongoing sales of kits and key components. We have also made good progress in other key areas including our Nu.Q^® NETs and Nu.Q^® Capture programs as we shift gears towards our goal of becoming a commercial company with products.”

See the financial results interview here: